Review



snap aso 3  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    ATCC snap aso 3
    Snap Aso 3, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 4314 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/snap aso 3/product/ATCC
    Average 98 stars, based on 4314 article reviews
    snap aso 3 - by Bioz Stars, 2026-05
    98/100 stars

    Images



    Similar Products

    98
    ATCC snap aso 3
    Snap Aso 3, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/snap aso 3/product/ATCC
    Average 98 stars, based on 1 article reviews
    snap aso 3 - by Bioz Stars, 2026-05
    98/100 stars
      Buy from Supplier

    99
    Croda International Plc 1 2 dipalmitoyl sn glycero 3 phosphocholine
    1 2 Dipalmitoyl Sn Glycero 3 Phosphocholine, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/1 2 dipalmitoyl sn glycero 3 phosphocholine/product/Croda International Plc
    Average 99 stars, based on 1 article reviews
    1 2 dipalmitoyl sn glycero 3 phosphocholine - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    93
    Croda International Plc 1 2 dipalmitoyl sn glycero 3 phosphocholine dppc
    1 2 Dipalmitoyl Sn Glycero 3 Phosphocholine Dppc, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/1 2 dipalmitoyl sn glycero 3 phosphocholine dppc/product/Croda International Plc
    Average 93 stars, based on 1 article reviews
    1 2 dipalmitoyl sn glycero 3 phosphocholine dppc - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    99
    Croda International Plc 1 2 distearoyl sn glycero 3 phosphocholine dspc
    1 2 Distearoyl Sn Glycero 3 Phosphocholine Dspc, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/1 2 distearoyl sn glycero 3 phosphocholine dspc/product/Croda International Plc
    Average 99 stars, based on 1 article reviews
    1 2 distearoyl sn glycero 3 phosphocholine dspc - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    93
    Croda International Plc 1 myristoyl 2 palmitoyl sn glycero 3 phosphocholine mppc
    Three-dimensional response surface plots are presented to examine the interaction effects between dependent and independent variables during formulation optimization. The figure provides a comprehensive overview of how particle size varies with drug quantity, DPPC, PEG-2000, and <t>MPPC.</t>
    1 Myristoyl 2 Palmitoyl Sn Glycero 3 Phosphocholine Mppc, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/1 myristoyl 2 palmitoyl sn glycero 3 phosphocholine mppc/product/Croda International Plc
    Average 93 stars, based on 1 article reviews
    1 myristoyl 2 palmitoyl sn glycero 3 phosphocholine mppc - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    99
    ATCC pc3 cells
    OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and <t>PC3</t> prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.
    Pc3 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pc3 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    pc3 cells - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    pc 3  (ATCC)
    99
    ATCC pc 3
    OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and <t>PC3</t> prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.
    Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pc 3/product/ATCC
    Average 99 stars, based on 1 article reviews
    pc 3 - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    ATCC non tumor hacat
    OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and <t>PC3</t> prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.
    Non Tumor Hacat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non tumor hacat/product/ATCC
    Average 99 stars, based on 1 article reviews
    non tumor hacat - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    Image Search Results


    Three-dimensional response surface plots are presented to examine the interaction effects between dependent and independent variables during formulation optimization. The figure provides a comprehensive overview of how particle size varies with drug quantity, DPPC, PEG-2000, and MPPC.

    Journal: International Journal of Pharmaceutics: X

    Article Title: Anti-EGFR liposomal drug delivery system loaded with AGY 2 potentiates the anti-cancer effect of AGY 2 against EGFR expressed pancreatic cancer

    doi: 10.1016/j.ijpx.2026.100544

    Figure Lengend Snippet: Three-dimensional response surface plots are presented to examine the interaction effects between dependent and independent variables during formulation optimization. The figure provides a comprehensive overview of how particle size varies with drug quantity, DPPC, PEG-2000, and MPPC.

    Article Snippet: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (MPPC), and DSPE-PEG2000-carboxy NHS (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethyleneglycol)-2000-NHS ester] (sodium salt)), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt), were purchased from Avanti Polar Lipids (Alabaster, AL, USA).

    Techniques: Formulation

    Three-dimensional response surface plots are presented to evaluate the interaction effects between dependent and independent variables during formulation optimization. This figure compiles response surface plots showing how entrapment efficiency varies with drug quantity, DPPC, PEG-2000, and MPPC.

    Journal: International Journal of Pharmaceutics: X

    Article Title: Anti-EGFR liposomal drug delivery system loaded with AGY 2 potentiates the anti-cancer effect of AGY 2 against EGFR expressed pancreatic cancer

    doi: 10.1016/j.ijpx.2026.100544

    Figure Lengend Snippet: Three-dimensional response surface plots are presented to evaluate the interaction effects between dependent and independent variables during formulation optimization. This figure compiles response surface plots showing how entrapment efficiency varies with drug quantity, DPPC, PEG-2000, and MPPC.

    Article Snippet: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (MPPC), and DSPE-PEG2000-carboxy NHS (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethyleneglycol)-2000-NHS ester] (sodium salt)), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt), were purchased from Avanti Polar Lipids (Alabaster, AL, USA).

    Techniques: Formulation

    OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.

    Journal: Oncology Reports

    Article Title: Sphingosine-1-phosphate receptor 1 enhances olfactory receptor 51E1-mediated inhibition of proliferation via Src/JNK signaling in prostate cancer cells

    doi: 10.3892/or.2026.9103

    Figure Lengend Snippet: OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.

    Article Snippet: LNCaP cells were obtained from the Korean Cell Line Bank, and Du145 and PC3 cells were purchased from the American Type Culture Collection.

    Techniques: Expressing, Cell Counting, Control, Knock-Out, Reverse Transcription, Real-time Polymerase Chain Reaction, Agarose Gel Electrophoresis, Cell Culture, RNA Sequencing, Olfactory